Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
Frangié
Carlos
C
Department of Nephrology, Georges Pompidou European Hospital, Paris, France.
Lefaucheur
Carmen
C
Medioni
Jacques
J
Jacquot
Christian
C
Hill
Garry S
GS
Nochy
Dominique
D
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D013927:Thrombosis / Q000139:chemically induced*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab